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Edited by Horst FeldmannAbstract Cathepsin S is unique among mammalian cysteine
cathepsins in being active and stable at neutral pH. We show that
autocatalytic activation of procathepsin S at low pH is a bimo-
lecular process that is considerably accelerated (~20-fold) by gly-
cosaminoglycans and polysaccharides such as dextran sulfate,
chondroitin sulfates A and E, and dermatan sulfate through elec-
trostatic interaction with the proenzyme. Procathepsin S is also
shown to undergo autoactivation at neutral pH in the presence of
dextran sulfate with t1/2 of 20 min at pH 7.5. This novel prop-
erty of procathepsin S may have implications in pathological
conditions associated with the appearance of active cathepsins
outside lysosomes.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cathepsin S (EC 3.4.22.27) is a single chain, non-glycosyl-
ated papain-like lysosomal cysteine protease that is, unusu-
ally, highly active and stable at neutral pH [1–3]. A
number of studies have indicated that cathepsin S is indis-
pensable for MHC class II-mediated antigen presentation
(reviewed in [4,5]). Moreover, inhibition of cathepsin S in
vivo has been shown to alter autoantigen presentation and
development of organ-speciﬁc autoimmunity, and therefore
cathepsin S is considered to be a potential target for autoim-
mune- and hyperimmune-disease therapy [6–9]. Due to its
high elastinolytic activity, it has been suggested that cathep-
sin S is involved in atherogenesis [10], vascular matrix
remodeling during angiogenesis [11] and promotion of cilia
motility in the lung [12]. In addition, increased expression
of cathepsin S has also been associated with the pathogene-
sis of Alzheimers disease [13], tumor invasion [14,15] and
muscular dystrophy [16].
Like other papain-like cysteine proteases, cathepsin S is
synthesized as an inactive zymogen, and is converted to
the mature form by limited proteolysis at low pH by other
proteases, or by autocatalytic processing which is a bimolec-
ular process. During activation, which is believed to occur in
the acidic environment of late endosomes or lysosomes, the*Corresponding author. Fax: +386 1 257 35 94.
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zyme thereby unmasking the active site of the enzyme (re-
viewed in [1]). Polysaccharides, with dextran sulfate as the
most frequently used model compound, were found to sub-
stantially accelerate processing of papain-like cathepsins,
including cathepsin S [17–20].
Due to the high stability and activity of the enzyme at
neutral pH, we investigated the pH-dependence of autocata-
lytic activation of procathepsin S and the inﬂuence of poly-
saccharides and ionic strength on the processing. Here, we
show that the proenzyme can be autoactivated at neutral
pH, making possible a role for cathepsin S in pathological
conditions associated with the extra-lysosomal activity of pa-
pain-like cathepsins.2. Materials and methods
2.1. Materials
Bz-Phe-Val-Arg-AMC (7-amido-4-methylcoumarin) and Z-Phe-
Arg-AMC were from Bachem (Bubendorf, Switzerland) and E-64
[trans-epoxysuccinyl-L-leucyl-amido-(4-guanidino)butane] from Pep-
tide Research Foundation (Osaka, Japan). Iodoacetic acid and poly-
ethylene glycol 6000 were from Serva (Heidelberg, Germany) and
dimethyl sulfoxide from Merck (Darmstadt, Germany). Heparin,
dextran sulfate, heparan sulfate, chondroitin sulfate, polylysine,
ADA [N-[2-acetamidol]-2-iminodiacetic acid], TES [N-Tris(hydroxy-
methyl)methyl-2-aminoethanesulfonic acid], HEPES [2-(4-(2-
hydroxyethyl)-1-piperazinyl)ethanesulfonic acid] and PIPES [pipera-
zine-1,4-bis(2-ethanesulfonic acid)] were from Sigma (St. Louis,
USA).
2.2. Expression and puriﬁcation of recombinant human procathepsin S
Recombinant procathepsin S was expressed in the form of inclu-
sion bodies in Escherichia coli strain BL21[DE3]pLysS, solubilized,
refolded and reoxidized as described previously [19]. Protein concen-
trations were determined from absorbance at 280 nm (Perkin–Elmer
k-18 spectrometer, USA) using the molar absorption coeﬃcients of
72685 and 35225 for procathepsin S and active cathepsin S, respec-
tively, calculated by the method of Pace et al. [21]. The active con-
centration of processed cathepsin S was determined by titration with
steﬁn A [22].
2.3. Processing and activation of procathepsin S
Autocatalytic activation of procathepsin S was studied by incuba-
tion (ﬁnal concentration 1–5 lM) at 37 C in 0.5 ml of the appropriate
buﬀer (see below) containing 2.5 mM dithiothreitol, in the absence and
presence of dextran sulfate, as described previously [20,23]. Aliquots of
10 ll were taken from the reaction mixture at the times indicated and
mixed with 2.5 ml of substrate solution (10 lM Bz-FVR-AMC in
0.1 M phosphate buﬀer, pH 6.5, containing 1 mM EDTA and 0.1%
(w/v) polyethylene glycol 6000). Fluorescence of the released AMC
was then monitored continuously for 1 min in a Perkin–Elmer LS-50
spectroﬂuorimeter (Norwalk, CT, USA) at excitation and emissionblished by Elsevier B.V. All rights reserved.
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ide in the assay was adjusted to 4% (v/v). The following processing buf-
fers were used: 0.1 M acetate buﬀer between pH 3.0 and 5.5; 0.1 M
phosphate buﬀer between pH 6.0 and 8.0 and 0.1 M Tris–HCl buﬀer
between pH 8.0 and 9.0. All processing buﬀers contained 1 mM
EDTA.Fig. 1. Autocatalytic processing of recombinant human procathepsin S. P
expressed in arbitrary ﬂuorescence units per unit time (dF/dt). (A) Processin
25 mM Tris–HCl buﬀer, pH 7.5 (d) and in 25 mM citrate buﬀer, pH 5.0 (.
followed by SDS–PAGE. Procathepsin S was incubated in 25 mM citrate buﬀ
DS. Low molecular mass standards are shown in the ﬁrst lane. Lane 0 co
procathepsin S processing at alkaline pH. Procathepsin S was incubated in 0
presence of 25 lg/ml DS and samples were taken every 20 min. Low molecula
before activation.Autocatalytic processing of procathepsin S was followed by 12.5%
SDS–PAGE under reducing conditions. 12 ll aliquots of the reaction
mixture (see above), with or without dextran sulfate, was taken at
appropriate times and processing was stopped by adding 4 ll of 4·
SDS–PAGE loading buﬀer containing 4% (v/v) b-mercaptoethanol
and 1% (w/v) SDS, and heating at 100 C for 5 min.roteolytic activity was assayed against 10 lM Bz-FVR-AMC and is
g mixtures were incubated in the presence of 25 lg/ml DS at 37 C in
). (B) Time dependence of the cleavage of procathepsin S at acidic pH
er, pH 5.0, containing 1 mM EDTA at 37 C in the presence of 25 lg/ml
ntains procathepsin S before activation. (C) SDS–PAGE analysis of
.1 M Tris–HCl buﬀer, pH 8.0, containing 1 mM EDTA at 37 C in the
r mass standards are shown in ﬁrst lane. Lane 0 contains procathepsin S
Table 1
Eﬀect of pH and dextran sulfate on the rate of procathepsin S
processing at 37 C
pH Half-time of procathepsin S processing (t1/2)
t1/2 (DS), min t1/2 (+DS), min
5.0 78 ± 5.0 4 ± 0.5
7.5 nd 18 ± 3.0
Half-times (t1/2) (±S.E.M.) of procathepsin S processing, in the absence
(DS) and in the presence (+DS) of 2.5 ll/ml DS, were estimated by
the discontinuous method. The procathepsin S concentration was
3 lM in all experiments. nd – no reaction detected.
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The N-terminal amino acid sequences of the samples, subjected to
SDS–PAGE under non-reducing conditions and blotted to a PVDF
membrane, were determined using an Applied Biosystems (USA)
PROCISE 492A protein sequencing system.3. Results
3.1. Processing of procathepsin S
In initial experiments, a dextran sulfate (DS) concentra-
tion of 25 lg/ml was found to be optimal for the processing
of procathepsin S at acidic pH (data not shown), in agree-
ment with previous data on cysteine cathepsins
[19,20,24,25], and was therefore used in all subsequent exper-
iments. Activation of procathepsin S was then investigated
as a function of pH in the presence of dextran sulfate. Since
our preliminary experiments suggested that procathepsin S
could be activated both at acidic and at neutral pH, we
investigated activation of the enzyme at pH 5.0 and 7.5.
The process was substantially faster at pH 5.0, with a
half-life of 4 min compared to 18 min at pH 7.5
(Fig. 1A; Table 1). A sigmoidal increase of cathepsin S
activity was observed at pH 7.5, suggesting a bimolecular
mechanism, in agreement with previous data on procathep-
sins B and K activation [20,26]. At pH 5.0, activation was
too rapid to allow the initial lag phase to be detected by
the discontinuous method. In the absence of dextran sulfate,
activation was 20-fold slower, and no activation was de-
tected at pH 7.5 (Table 1). The ﬁnal activity of the pro-
cessed cathepsin S was unaﬀected by DS (data not shown),Fig. 2. pH proﬁle of recombinant human procathepsin S processing in the ab
37 C in 0.1 M acetate buﬀer (pH 4.0–5.0), 0.1 M phosphate buﬀer (pH 6.0–
measurements as described in Section 2. Results are presented as relative acin agreement with related results with chondroitin sulfate
[27]. Moreover, these results also indicated that the active
enzyme was stable and did not undergo further degradation,
as observed for recombinant cathepsin H [23].
In order to verify that activation was accompanied by lim-
ited proteolysis, processing of the enzyme was followed by
SDS–PAGE in the presence of DS at acidic and neutral pH.
At pH 5.0 rapid cleavage was observed, paralleling the enzyme
activity experiments (Fig. 1B). Processing was complete, even
at pH 8.0, although minor degradation of the protein was ob-
served (Fig. 1C). However, no processing intermediates were
observed at either pH value. N-terminal amino acid sequences
were determined on the same samples. A single sequence,
AQLHK, was obtained for procathepsin S, identical to that
deduced from the cDNA sequence [28,29]. The sequence of ac-
tive cathepsin S started with SNPNR, an extension of 6 resi-
dues over the sequence of natural cathepsin S [30]. Such
extensions of 2–6 amino acid residues are common for most re-
combinant cysteine cathepsins. However, they do not aﬀect the
catalytic eﬃciency of the enzymes [31].
3.2. pH-activity proﬁle of recombinant human procathepsin S
processing
In order to investigate the pH-proﬁle of procathepsin S
autocatalytic activation, we compared the activities of cathep-
sin S after 30 min of incubation at 37 C in the pH range be-
tween 3.0 and 9.0, in the absence and presence of DS (Fig.
2). The 30 min time point was selected as the time, in the pres-
ence of DS, by which activation of cathepsin S at both acidic
and neutral pH was complete (Fig. 1A). The activity proﬁle
in the absence of DS showed a single maximum between pH
4.0 and 5.0, typical for papain-like cathepsins [1,31]. In con-
trast, the activity proﬁle in the presence of DS exhibited two
maxima: a sharp peak at pH 5.0 and a broader peak at neutral
pH (7.0–8.0) (Fig. 2).
To exclude any artifacts of the buﬀer systems and to
investigate any role of buﬀer composition on the eﬃciency
of procathepsin S activation at neutral pH, the processing
in the presence of DS was analyzed at pH 7.2 using several
buﬀer systems: ADA, TES, TRIS, PIPES, HEPES and BES.
All the buﬀers contained 1 mM EDTA and NaCl was added
to the buﬀers to achieve an ionic strength (I) of 0.025. No
signiﬁcant diﬀerences in the rate of processing were observedsence and presence of DS. Procathepsin S was incubated for 30 min at
8.0) and 0.1 M Tris–HCl buﬀer (pH 8.0–9.0), followed by the activity
tivity.
Table 2
Eﬀect of polysaccharides on procathepsin S processing at pH 5.0 and
37 C
Polysaccharide t1/2 (min)
None 78 ± 5.0
Dextran sulfate 4 ± 0.5
Heparin 31 ± 7.9
Heparan sulfate 76 ± 10.8
Chondroitin sulfate A <4.0
Chondroitin sulfate E <4.0
Hyaluronic acid 65 ± 11.3
Dermatan sulfate <4.0
Half-times (t1/2) (±S.E.M.) of procathepsin S processing, in the pres-
ence of diﬀerent polysaccharides at concentrations of 2.5 ll/ml, were
estimated by the discontinuous method. The procathepsin S concen-
tration was 10 lM in all experiments.
Fig. 3. Eﬀect of ionic strength on the rate of procathepsin S processing
at diﬀerent pHs, in the presence and absence of dextran sulfate.
Procathepsin S was incubated for 15 min in 25 mM Tris–HCl buﬀer,
pH 7.0 (d) and in 25 mM citrate buﬀer, pH 5.0 (.), both in the
presence of 25 lg/ml DS, and for 60 min in 25 mM citric buﬀer, pH 4.0
(n) in its absence. Ionic strengths of solutions are based on the
computer program ‘‘Java Buﬀer Calculator’’ and varied by addition of
NaCl. All other experimental details were as described under Section 2.
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cessing rate is independent of buﬀer composition (data not
shown).
3.3. Autocatalytic processing of recombinant human
procathepsin S in the presence of glycosaminoglycans
Since dextran sulfate accelerates the processing of cathepsin
S it was important to investigate the possible eﬀect of more
physiologically relevant glycosaminoglycans. Activation exper-
iments were therefore performed at pH 5.0 in the presence of
25 lg/ml concentrations of heparin, heparan sulfate, chondroi-
tin sulfates A and E, hyaluronic acid, dermatan sulfate, with
DS as the control. Chondroitin sulfates A and E, and derma-
tan sulfate were found to be at least as eﬃcient as DS,
although more precise values could not be obtained since the
processing was too fast. Heparin was only moderately eﬃcient
(2.5-fold acceleration), whereas heparan sulfate and hyalu-
ronic acid had no eﬀect (Table 2).
3.4. Eﬀect of ionic strength on the rate of procathepsin S
processing
Due to their negative charge, glycosaminoglycans and
other charged polysaccharides interact with their target pro-
teins primarily via electrostatic interactions. Therefore, we
investigated the inﬂuence of ionic strength on the rate of
procathepsin S processing. The incubation time selected
was the time needed, in the absence of NaCl, for activation
of at least 50% of the procathepsin S. Thus activity was
measured after 15 min in the presence of DS (at pH 5.0
and 7.0), and after 60 min (pH 4.0) in its absence. As shown
in Fig. 3, the eﬀect of ionic strength is dramatic, especially
at neutral pH, where processing within the initial 15 min
was almost completely abolished at an ionic strength of
0.1. A moderate eﬀect was observed at pH 5.0 (60% activity
reduction), whereas only a minor eﬀect was seen in the ab-
sence of DS, indicating a crucial role of charge–charge inter-
actions between DS and procathepsin S in the rate of
cathepsin S autocatalytic activation.4. Discussion
Glycosaminoglycans and dextran sulfate have long been
known to be able to accelerate activation of cysteine cathepsins
[17–20]. The same was found to be true for cathepsin S withdextran sulfate, chondroitin sulfates A and E, and dermatan
sulfate. Their interaction was shown to be primarily ionic
and can be completely abolished at even moderate ionic
strengths (Fig. 3). Since they bind to mature enzymes with only
moderate aﬃnity [32,33], it suggests that the glycosaminogly-
can binds to the propeptide of procathepsin S and possibly
of other cathepsins. The crystal structure of procathepsin S
is not known but the propeptide contains a large number of
positively charged residues – eight histidines, nine lysines and
ﬁve arginines – all positioned in clusters, strongly supporting
the proposal that this is the primary site of interaction with
glycosaminoglycans. Their binding to the propeptide thus ap-
pears to be important for the initial step of procathepsin S pro-
cessing. The diﬀerences in catalytic eﬃciency observed for
diﬀerent glycosaminoglycans and dextran sulfate (Table 2),
as for the interactions of glycosaminoglycans with cathepsin
B and papain [32,33], presumably reﬂect the diﬀerences in
backbone structure of diﬀerent polysaccharides and only to a
minor extent the diﬀerences in their charge density. This could
possibly explain only a minor eﬀect of heparin as compared
with chondroitin sulfates A and E. The location of glycosami-
noglycans in lysosomes as the result of proteoglycan recycling,
in the extracellular matrix, at the cell surface and at basement
membranes [34], supports the proposal that they are involved
in in vivo processing, not only of cathepsin S, but also of other
cysteine cathepsins both inside and outside lysosomes.
For a long time lysosomal cysteine proteases were believed
to be produced autocatalytically at acidic pH only. However,
procongopain, a parasitic cysteine protease from Trypanosoma
congolense, was recently found to be capable of autocatalytic
activation at neutral pH [35]. Here, we have shown that mam-
malian procathepsin S can be autocatalytically activated at
neutral pH in the presence of dextran sulfate and related gly-
cosaminoglycans, a feature not observed before for any of
the related cathepsins. An amino acid sequence alignment of
the propeptides of cysteine cathepsins [1] shows that the num-
O. Vasiljeva et al. / FEBS Letters 579 (2005) 1285–1290 1289bers of arginines and lysines in the propeptides of the related
cathepsins K, L, V and F are similar (5–9), whereas the num-
bers of histidines are considerably smaller (1–6) than the eight
histidines in cathepsin S propeptide. It is likely that these addi-
tional histidines are involved in interactions with the negatively
charged residues of the mature part of the enzyme. Histidines
become deprotonated at pH values around neutral and would
thereby weaken propeptide binding to the mature enzyme part.
This could facilitate glycosaminoglycan binding to the propep-
tide and, consequently, zymogen activation. The appearance of
the second peak of activation of procathepsin S around neutral
pH in the presence of glycosaminoglycans could be explained
by this mechanism. It would appear that cathepsin S is there-
fore unique among the mammalian cysteine cathepsins.
However, the mechanism involving histidine deprotonation
does not account for the zymogen processing at acidic pH in
the absence of glycosaminoglycans. This could be explained
by the substantially weaker binding of propeptide to the ma-
ture part of the enzyme at lower pH, which is in agreement
with the data for binding of synthetic propeptides to cathepsin
B [36] and cathepsin L [37].
Due to the high stability of cathepsin S at neutral pH [38], its
high elastinolytic potential [39,40], and its ability to activate
other cysteine cathepsins [41] cathepsin S can be extremely
harmful in the extracellular environment. Our ﬁnding that pro-
cathepsin S can undergo autoactivation at neutral pH further
supports this idea. In fact, cathepsin S has been observed in
the extracellular environment in various pathological condi-
tions, from cancer progression [14,15], to rheumatoid arthritis
[42], atherogenesis [10] and muscular dystrophy [16]. It is pos-
sible therefore that cathepsin S participates in extracellular
proteolytic cascades, directly by cleavage of extracellular sub-
strates and/or indirectly through activation of other lysosomal
proteases, thereby amplifying their degradative capacity,
potentially leading to pathological damage, including facilitat-
ing the penetration of tissues by cancer cells [43].
In conclusion, our results show that procathepsin S is capa-
ble of rapid autocatalytic activation, not only at acidic pH but
also at neutral pH in the presence of glycosaminoglycans,
which could be an important mechanism for regulating its
activity and that of other cysteine cathepsins, not only inside
lysosomes but also in the cytosol or extracellular space where
cathepsin S is often found in various pathologies.
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